News >

Gemcitabine-Free Regimen Leads to Improved Survival in Metastatic Pancreatic Cancer

Published: Thursday, Feb 16, 2017

Results of the randomized phase II GERCOR trial concluded that patients with metastatic pancreatic cancer saw numerically better survival rates with a gemcitabine-free regimen when compared with a conventional gemcitabine regimen.  

With a median follow-up of 16.9 months, the LV5FU2 group had a median overall survival of 11.4 months compared with 9.2 months with the gemcitabine regimen. Overall survival rates favored the LV5FU2 group at 12 (48% vs 41%) and 18 months (34% vs 13%).


  1. Dubreuil O, Bachet JB, Hammel P, et al. Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic adenocarcinoma: A GERCOR randomized phase II study (AFUGEM). J Clin Oncol. 2017;35(suppl 4S; abstr 350).
  2. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691-1703. doi:10.1056/NEJMoa1304369.
  3. Greenhalf W, Ghaneh P, Neoptolemos JP, et al; European Study Group for Pancreatic Cancer Investigators. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst. 2014;106(1):djt347. doi:10.1093/jnci/gjt347.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication